OKYO Pharma Limited.
OKYO.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
OKYO Pharma Limited is a biopharmaceutical company focused on the discovery and development of novel therapies for inflammatory dry eye disease and other ocular indications. Their lead product candidate, OK-101, is a lipid conjugated chemerin peptide agonist targeting the ChemR23 G-protein coupled r...Show More
Better Health for All
0
No evidence available to assess OKYO Pharma Limited on Better Health for All.
Fair Money & Economic Opportunity
0
No evidence available to assess OKYO Pharma Limited on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess OKYO Pharma Limited on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess OKYO Pharma Limited on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No specific, concrete data points relevant to OKYO.US or the 'Honest & Fair Business' ethical value were found in the provided articles. All articles explicitly stated that no such information was available or that the content was irrelevant to the company or the ethical value being assessed.
1
Kind to Animals
-30
OKYO Pharma, as a clinical-stage biopharmaceutical company, develops therapeutics for inflammatory eye diseases and ocular pain. The company uses animals for pre-clinical studies.
1
,
2
OK-201 demonstrated a reduced corneal pain response in an animal model.
3
Development plans for OK-101 aim to skip Phase 1 safety trials and proceed directly to Phase 2 efficacy trials.
4
However, the extent of animal testing, specific animal welfare practices, and adoption of alternative testing methods are not disclosed.
5
,
6
The company's reliance on animal testing without demonstrable efforts to minimize harm or adopt alternatives results in a negative score. Insufficient information is available regarding specific animal welfare practices, alternative testing methods, or efforts to reduce animal usage.
7
,
8
**Score: -30, Confidence: 60**
No War, No Weapons
0
OKYO.US is a biopharmaceutical company focused on developing therapies for inflammatory eye diseases and ocular pain. The company has 0% revenue from arms or defense contracts, no dual-use technology with military applications, and no sales to embargoed or sanctioned regimes.
1
It also has no defense business to oversee, no exports requiring end-user certificates, and no defense-related lobbying.
2
Furthermore, the company has zero exposure to controversial weapons, no defense assets to divest, and no procurement from conflict-affected or high-risk areas.
3
Planet-Friendly Business
0
No specific, concrete data points related to planet-friendly business practices, environmental performance, or sustainability metrics for OKYO.US are available in the provided articles. The articles explicitly state that sustainability data is unavailable or that no environmental, social, or governance (ESG) metrics are provided.
1
Respect for Cultures & Communities
0
No evidence available to assess OKYO Pharma Limited on Respect for Cultures & Communities.
Safe & Smart Tech
0
OKYO.US has no documented data breaches or incidents of unauthorized data use.
1
The company's privacy policy outlines user rights to access, correct, erase, and transfer data.
2
It also states that data retention is based on need and legal requirements, and mentions compliance with GDPR and other relevant UK and US regulations.
3
Zero Waste & Sustainable Products
0
No specific, concrete evidence was found in the provided articles regarding OKYO.US's performance on any of the Zero Waste & Sustainable Products KPIs. The articles primarily discuss general sustainability principles within the pharmaceutical industry, clinical trial supply chain challenges, or OKYO Pharma's financial and corporate structure, without providing data on waste diversion, product recyclability, packaging sustainability, waste reduction initiatives, or any other relevant metrics for OKYO.US.
1